Financial Performance - Operating revenue for the period was approximately ¥116.06 million, representing a year-on-year increase of 15.68%[5] - Net profit attributable to shareholders was approximately ¥14.85 million, an increase of 5.10% compared to the same period last year[5] - Basic and diluted earnings per share remained unchanged at ¥0.07[5] - The total profit for Q1 2017 was CNY 15,667,638.60, an increase from CNY 12,613,318.12 in the previous year, representing a growth of approximately 24.4%[27] - The net profit for Q1 2017 reached CNY 13,365,432.38, compared to CNY 10,721,049.08 in the same period last year, marking an increase of about 24.5%[27] Cash Flow - Net cash flow from operating activities was negative at approximately -¥3.30 million, a decrease of 129.99% compared to the previous year[5] - Operating cash flow net amount decreased by 129.99% to CNY -3,302,727.07 from CNY 11,013,387.09 due to a reduction in sales receipts[12] - Cash inflow from operating activities totaled CNY 141,171,116.10, slightly down from CNY 142,915,014.31 in the previous year, indicating a decrease of about 1.2%[30] - The company reported a negative cash flow from operating activities of CNY -7,477,444.12, contrasting with a positive cash flow of CNY 12,303,052.84 in the previous year[32] - The net cash flow from investment activities was CNY 11,548,499.52, down from CNY 104,456,582.24 in the previous year, indicating a decrease of about 88.9%[30] Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥972.25 million, a decrease of 0.04% compared to the end of the previous year[5] - Total liabilities decreased to CNY 94,818,578.99 from CNY 109,372,482.03[17] - Total equity increased to CNY 877,434,968.97 from CNY 863,310,565.54[17] - The company's total assets as of the end of Q1 2017 were CNY 944,165,373.77, a marginal increase from CNY 944,059,466.27 at the end of the previous quarter[21] - Total liabilities for Q1 2017 amounted to CNY 105,583,161.31, down from CNY 118,842,686.19 in the previous quarter, indicating a decrease of 11.1%[21] Shareholder Information - The total number of shareholders at the end of the reporting period was 22,525[9] - The largest shareholder, Gao Bo Investment (Hong Kong) Co., Ltd., held 37.39% of the shares, amounting to 74,784,000 shares[9] Other Financial Metrics - The weighted average return on equity was 1.72%, a decrease of 0.08 percentage points from the previous year[5] - The company reported a total of approximately ¥2.99 million in non-recurring gains and losses for the period[8] - The company received government subsidies related to research and development amounting to approximately ¥517,163.04[7] - Non-operating income increased by 224.02% to CNY 525,944.24 from CNY 162,320.50, attributed to an increase in research and development subsidies received[12] - Financial expenses increased significantly to CNY 349,086.86 from CNY -291,419.59, mainly due to exchange rate fluctuations[12] Investment Activities - The company received CNY 336,000,000.00 from investment recoveries, compared to CNY 197,000,000.00 in the previous year, showing an increase of approximately 70.7%[30] - Cash inflow from investment activities was CNY 339,850,610.72, up from CNY 200,740,718.50, reflecting an increase of approximately 69.3%[30]
维力医疗(603309) - 2017 Q1 - 季度财报